X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
L1-79 (DL-alpha-Methyltyrosine) is a tyrosine hydroxylase inhibitor which is under phase 2 clinical development . It is designed to improve the core socialization and communication symptoms of autism spectrum disorder (ASD).
Lead Product(s): Methyltyrosine
Therapeutic Area: Neurology Product Name: L1-79
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 20, 2023
Details:
As part of investment in Yamo to support a Phase 2 study of L1-79 in adolescents and adults with ASD. L1-79, the company’s lead candidate, is a tyrosine hydroxylase inhibitor designed to modulate the catecholaminergic pathways implicated in ASD.
Lead Product(s): Methyltyrosine
Therapeutic Area: Neurology Product Name: L1-79
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: The Autism Impact Fund
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Financing November 10, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
